Searchable abstracts of presentations at key conferences in endocrinology

ea0049gp184 | Pituitary | ECE2017

Hormonal and metabolic effects of long-term cabergoline withdrawal in patients with hyperprolactinemia

Auriemma Renata Simona , Blasio Chiara , Grasso Ludovica Francesca Stella , Galdiero Mariano , Negri Mariarosaria , Pivonello Claudia , Granieri Luciana , Colao Annamaria , Pivonello Rosario

Hyperprolactinemia is associated with abnormalities in glucose and lipid profile with development of insulin resistance and metabolic syndrome (MetS), which have been found to be improved by treatment with cabergoline (CAB). The current study aimed at investigating hormonal and metabolic effects of long-term CAB withdrawal in patients with prolactinomas. In 46 patients (37 F, 9 M, aged 34.5±11.5 yrs, 36 microadenomas and 10 macroadenomas) anthropometric (weight, BMI, wais...

ea0049ep34 | Adrenal cortex (to include Cushing's) | ECE2017

The treatment with dual release hydrocortisone in patients with adrenal insufficiency: correlation between change of the evening cortisol exposure time profile and change in metabolic profile, depression status and quality of life

Simeoli Chiara , Ferrigno Rosario , Pivonello Claudia , Auriemma Renata Simona , Negri Mariarosaria , Di Gennaro Gilda , Iacuaniello Davide , De Martino Maria Cristina , Colao Annamaria , Pivonello Rosario

Conventional glucocorticoids (CGCs) are unable to mimic physiological cortisol rhythm in adrenal insufficiency (AI), resulting in increased metabolic morbidity and impaired quality of life (QoL). Non-physiological cortisol pattern and elevated evening cortisol levels may be responsible for the increased risk of metabolic disorders observed in AI patients under CGCs. Once daily dual-release-hydrocortisone (DR-HC), which better reproduces physiological daily cortisol profile, si...

ea0041gp17 | Adrenal (1) | ECE2016

Improved evening and nocturnal cortisol exposure time profile in patients with adrenal insufficiency treated with dual release hydrocortisone: correlation with improvement in metabolic profile

Simeoli Chiara , Ferrigno Rosario , De Martino Maria Cristina , Auriemma Renata Simona , Pivonello Claudia , Negri Mariarosaria , Iacuaniello Davide , Di Gennaro Gilda , Colao Annamaria , Pivonello Rosario

Conventional glucocorticoids (GCs) are unable to mimic physiological cortisol rhythm in adrenal insufficiency (AI), with a significant impact on morbidity and mortality. Possible explanations are supra-physiological doses and impaired cortisol profile. In particular, elevated evening cortisol levels were related to glucose tolerance and insulin sensitivity alterations and visceral obesity. Once-daily-dual-release-hydrocortisone (OD-DR-HC), better reproducing the physiological ...

ea0041ep583 | Endocrine Disruptors | ECE2016

Thyroid diseases in the ‘Land of Fires’: results of a single center screening in Acerra (Naples)

Simona Auriemma Renata , Cozzolino Mariaconcetta , Belli Arturo , Fierro Gaetano , Messina Gaetana , De Luca Renato , De Simone Teresa , Rivezzi Matteo , Galdiero Mariano , de Angelis Cristina , Pivonello Rosario , Colao Annamaria

Introduction: Environmental toxins, including those deriving from illegal and hazardous disposal of urban and chemical waste, are known to act as endocrine disruptors and to increase the risk of malignancy and cancer mortality. The present study aimed at investigating prevalence and characteristics of thyroid diseases in the area of Acerra, a town in the perimeter of the so called ‘Land of Fires’.Methods: The screening included subjects aged &#...

ea0037gp.01.03 | Adrenal | ECE2015

Effect of the switch from conventional glucocorticoids to ‘dual release hydrocortisone' in adult patients with primary and secondary adrenal insufficiency: a 6-month multicentre study

Pivonello Rosario , Simeoli Chiara , Isidori Andrea M , Ciresi Alessandro , Savastano Silvia , Auriemma Renata S , Graziadio Chiara , Di Somma Carolina , Giordano Carla , Lenzi Andrea , Colao Annamaria

Adrenal insufficiency (AI) requires life-long glucocorticoid (GC) treatment, which is associated with an increased risk of metabolic syndrome (MS), probably due to cortisol overexposure for multiple drug daily doses, together with an impairment of quality of life (QoL). Moreover treatment compliance (TC) is reported to be suboptimal in AI patients. The current study aimed at investigating the impact of the switch from twice/thrice daily conventional GCs to once daily dual-rele...

ea0037gp.19.08 | Pituitary–Acromegaly | ECE2015

Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly

Auriemma Renata S , Grasso Ludovica F S , Galdiero Mariano , Pivonello Claudia , Salzano Ciro , Negri Mariarosaria , Angelis Cristina de , Colao Annamaria , Pivonello Rosario

Somatostatin analogues (SA) are known to revert acromegalic cardiomyopathy mainly in young patients with short disease duration, whereas pegvisomant (PEG) reportedly improves cardiac structure and performance in patients resistant to SA. To date, no data are available on the effects of long-term SA+PEG on cardiovascular complications. The current study aimed at investigating the effects of long-term SA+PEG on cardiac structure and performance in acromegaly. Thirty-six acromega...

ea0037gp.26.10 | Thyroid – hypothyroidism | ECE2015

HLA-DR in Hashimoto's thyroiditis

Jabrocka-Hybel Agata , Skalniak Anna , Pietkowski Jakub , Turek-Jabrocka Renata , Vyhouskaya Palina , Tsang Adrian , Lizis-Kolus Katarzyna , Sokolowski Grzegorz , Pach Dorota , Hubalewska-Dydejczyk Alicja

Background: The human leukocyte antigen (HLA) cluster is a genetic region that has been associated with multiple autoimmune disorders, also with autoimmune thyroid diseases. Plenty attempts to establish the significance of class II HLA-DR in Hashimoto’s thyroiditis (HT) development were undertaken in the past; however, reports are rather divergent. This might be caused by different criteria used to diagnose HT. There is however an alternative hypothesis, according to whic...

ea0035p29 | Adrenal cortex | ECE2014

The treatment with glucocorticoids in congenital adrenal hyperplasia: short- and long-term effects of the switch from conventional glucocorticoids to ‘dual release' hydrocortisone on metabolic and hormonal profile

Simeoli Chiara , Mannarino Teresa , De Martino Maria Cristina , Cozzolino Alessia , Iacuaniello Davide , De Leo Monica , Auriemma Renata S , Di Somma Carolina , Colao Annamaria , Pivonello Rosario

Life-long glucocorticoid (GC) treatment is needed in patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency in order to replace cortisol deficiency and to control ACTH and consequently androgen levels. Therefore, patients with CAH tend to have an increased risk of metabolic syndrome (MS), probably due to cortisol overexposure, caused by multiple daily doses of conventional GCs, unable to mimic cortisol circadian rhythm. The current study aimed at i...

ea0035p454 | Diabetes complications | ECE2014

Vasoinhibins are natural inhibitors of angiogenesis in the vitreous and are impaired in patients with diabetic retinopathy

Triebel Jakob , Moreno-Vega Aura Ileana , Vazquez-Membrillo Miguel , Garcia-Franco Renata , Macotela Yazmin , Lopez-Star Ellery , Escalera Gonzalo Martinez de la , Clapp Carmen

With preterm regression of the hyaloid vascular system, the human vitreous becomes devoid of blood vessels and maintains an avascular, transparent state throughout life. However, diseases of the developing and mature retina, such as retinopathy of prematurity or proliferative diabetic retinopathy (PDR), often result in the invasion of blood vessels into the vitreous, with a risk of causing vitreous hemorrhage, retinal detachment and, consequently, loss of vision or blindness. ...

ea0035p865 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Effect of chronic treatment with cabergoline and testosterone replacement on metabolic parameters in male patients with prolactinomas and hypogonadism

Galdiero Mariano , Auriemma Renata S , Vitale Pasquale , Calzo Fabio Lo , Salzano Ciro , Ferreri Lucia , Cariati Federica , Coppola Giorgio , Colao Annamaria , Pivonello Rosario

Generously supported by IPSEN)-->Hyperprolactinemia is reportedly associated with impaired metabolic profile, particularly in patients with concomitant hypogonadism. The current study aimed at investigating the effects of 12 and 24 month-continuous cabergoline (CAB) treatment on metabolic profile in male hyperprolactinemic patients. Thirty-two men with prolactinomas, including 22 with testosterone < 8 nmol/l (HG, 69%) and 10 with...